Ming-Mo Hou
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Papers in
-
- Hepatocellular Carcinoma Treatment and Prognosis 2
- Oncology 2
- Cancer Treatment and Pharmacology 1
- Cancer Immunotherapy and Biomarkers 1
- Co-authors
- Aung Naing (4 shared papers)Filip Jankú (4 shared papers)Jennifer J. Wheler (3 shared papers)Apostolia Maria Tsimberidou (3 shared papers)Razelle Kurzrock (3 shared papers)Karen H. Lu (3 shared papers)David S. Hong (4 shared papers)Ralph Zinner (3 shared papers)
- Journals
- Oncotarget (2 papers)European Journal of Nuclear Medicine and Molecular Imaging (1 paper)Biomedical Journal (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)BMC Cancer (1 paper)
- Partner nations
- TaiwanUnited StatesChina
In The Last Decade
Ming-Mo Hou
12 papers receiving 1.3k citations
Ming-Mo Hou's Hit Papers
Peers
Comparison fields: 5 of 53
- Hepatology 570
- Oncology 545
- Immunology 200
- Pathology and Forensic Medicine 141
- Cancer Research 103
Countries citing papers authored by Ming-Mo Hou
This map shows the geographic impact of Ming-Mo Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming-Mo Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming-Mo Hou more than expected).
Fields of papers citing papers by Ming-Mo Hou
This network shows the impact of papers produced by Ming-Mo Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming-Mo Hou. The network helps show where Ming-Mo Hou may publish in the future.
Co-authors
The 25 scholars most cited alongside Ming-Mo Hou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Hit paper breakdown → | 2020 | 1039 |
| 2 | 2020 | 118 | |
| 3 | 2014 | 54 | |
| 4 | 2020 | 31 | |
| 5 | 2021 | 24 | |
| 6 | 2016 | 20 | |
| 7 | 2014 | 11 | |
| 8 | 2016 | 9 | |
| 9 | Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. | 2014 | 9 |
| 10 | 2015 | 6 | |
| 11 | 2024 | 4 | |
| 12 | Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations. | 2012 | 3 |
About Ming-Mo Hou
Ming-Mo Hou is a scholar working on Hepatology, Oncology, Reproductive Medicine, Pulmonary and Respiratory Medicine and Hematology, having authored 12 papers that have together received 1.3k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Lung Cancer Treatments and Mutations (1 paper), Cancer Mechanisms and Therapy (1 paper), Ovarian cancer diagnosis and treatment (1 paper), Esophageal Cancer Research and Treatment (1 paper), Cancer Treatment and Pharmacology (1 paper), Cancer Immunotherapy and Biomarkers (1 paper) and Cholangiocarcinoma and Gallbladder Cancer Studies (1 paper). The work is most often cited by research in Hepatology (570 citations), Oncology (545 citations), Immunology (200 citations), Pathology and Forensic Medicine (141 citations) and Cancer Research (103 citations). Ming-Mo Hou has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Aung Naing, Filip Jankú, Jennifer J. Wheler, Apostolia Maria Tsimberidou, Razelle Kurzrock, Karen H. Lu, David S. Hong, Ralph Zinner, Siqing Fu and Robert Louis Coleman. Their work appears in journals such as Oncotarget, European Journal of Nuclear Medicine and Molecular Imaging, Biomedical Journal, Cancer Chemotherapy and Pharmacology and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.